36 results about "Differentiation Agents" patented technology

The present application describes various applications of the non-expansion protocol for the preparation of an injectable autologous cell mixture of the present invention that can be used to prevent symptoms in a number of indications. Cells are isolated from surgically derived tissue and are at least partially disaggregated from each other. The heterologous cell mixture is mixed with growth factors, differentiation agents, extracellular matrix proteins and/or microspheres and injected into the patient without cell expansion. The harvesting of tissue, cell isolation, and injection are performed within a single surgical procedure lasting only minutes to hours.

The invention provides icariin application in inducing stem cell in vitro orientation differentiates to several single type cells. The stem cell said includes embryonic stem cell, nerve stem cell and marrow mesenchyme stem cell. The single type cell includes nerve cell, bone cell, islet cells and endothelial cell. This invention also relates to application of the single type cell in preparing medicine of stem cell transplant curing nerve degenerative diseases, and its application in preparing cell differentiation agent that used to repair recovery injured nerve tissue, and its application in high efficiency drug effect screening model rebuilding and initial screening and estimating by using the model. The new applications of the icariin is extended in this invention, the fact of icariin contains pharmacy activity clarified, so it provides material basis for Chinese traditional medicine prevention and cure effect. The clarifying of drug effect mechanism provides reference for new medicine Chinese metical modern development with self-owned intellectual property right.

It has been found that when pluripotent stem cells are cultured in the presence of hepatocyte differentiating agents, a population of cells is derived that has a remarkably high proportion of cells with a stem cell phenotype. In one example, human embryonic stem cells are allowed to form embryoid bodies and then mixed with the differentiation agent n-butyrate, optionally supplemented with maturation factors. In another example, n-butyrate is added to human embryonic stem cells in feeder-free culture. A remarkably homogeneous population of cells was obtained in both methods, consisting primarily of cells with morphological characteristics of hepatocytes, expressing characteristic surface markers of hepatocytes, and also possessing enzymatic and biosynthetic roles important for liver function. Since hepatocytes readily proliferate in culture, this system provides a rich source of hepatocyte lineage cells for various uses, such as drug screening and supplementation of liver function in clinical therapy.

The present invention provides a method of inducing undifferentiated cells into induced osteoblasts. The method includes: A) a step of providing an induced osteoblast differentiation inducing agent obtained by culturing chondrocytes capable of hypertrophication in a differentiation agent producing medium containing dexamethasone, β-glycerophosphate, ascorbic acid and a serum component; and B) a step of culturing the undifferentiated cells in an undifferentiated cell culture medium containing the induced osteoblast differentiation inducing agent and a medium component, to differentiate the undifferentiated cells into the induced osteoblasts.

The present invention provides an agent obtainable by culturing a chondrocyte capable of hypertrophication in a differentiation agent producing medium, wherein the differentiation agent producing medium comprises at least one conventional osteoblast differentiation component selected from the group consisting of glucocorticoid, β-glycerophosphate and ascorbic acid. The differentiation agent producing medium may comprise all of glucocorticoid, β-glycerophosphate and ascorbic acid.

A method of preparing neural precursor cells by exposing pluripotent stem cells or neural stem cells to a differentiation agent. The agent is a pyridine analog, which in preferred embodiments is a phenylethynyl-substituted or phenylazo-substituted pyridine. In other embodiments, a method of enhancing neural precursor cell survival is provided in which the survival is enhanced by exposure to the pyridine analog. In further embodiments, a method of preparing neuronal cells is provided in which pluripotent or neural stem cells exposed to the pyridine analog are then incubated without the pyridine analog, resulting in differentiation into neurons, astrocytes and oligodendrocytes. These methods may be used in toxicological screens, e.g., to evaluate the neurotoxicity of a test compound.

The present invention relates to a pharmaceutical composition for the treatment and prevention of cancer and the preparation method thereof, especially to a cell differentiation agent named CDA-II which is prepared by reverse phase chromatography of fresh human urine. The pharmaceutical composition is effective for the treatment and prevention of cancer. The active components in CDA-II contain differentiation inducers, differentiation helper inducers and an anticachexia agent, which act cooperatively to achieve the best therapeutic effect.

The invention discloses a special-effect stem-cell in-vitro induction technology. The special-effect stem-cell in-vitro induction technology includes: separating and culturing human umbilical cord stem cells, to be more specific, using the human umbilical cord stem cells, taking human umbilical cord Wharton's jelly in a sterile manner, collecting cell suspension, changing the suspension when primary culture is performed for 24 hours, and changing the suspension when the primary culture is performed for 48 hours; performing primary culture for 7 days, digesting with trypsin if cell flocking is observed and then performing passage into a new bottle, and discarding suspended cells, wherein most of the human umbilical cord stem cells firmly attach to the bottle wall; adding a whole culture medium to start passage culture, changing the culture liquid every 3 days, and performing continuous passage for 3 generations; performing in-vitro human umbilical cord stem cell induction, to be more specific, selecting the stem cells with appropriate passage time and within 3 generations, changing the liquid, adding an induction differentiation agent 5-azacytidine, adding a liver cell growth factor HGF, basic growth factors EGF+bFGF and a stem cell factor SGF, and performing in-vitro induction for 24 hours. By the latest-generation in-vitro induction technology, the target homing rate of the in-vivo stem cells is 100%.

The present invention provides new compositions and methods for treatment of intracellular parasites. The compositions comprise one or more hydroxamic acids in an amount sufficient to interfere with the activity of one or more histone deacetylases in the intracellular parasites. The compositions and methods can be used to treat members of the Apicomplexa group of intracellular parasites.

The invention provides a planting method for promoting delayed picking of kiwifruit, which belongs to the field of kiwifruit planting. Before planting, the scions of grafted kiwifruit seedlings are soaked in self-made differentiation agent in order to achieve the purpose of delayed picking. The kiwifruit seedlings are pruned and fertilized according to the growth needs and fertilizer requirementsof kiwifruit plants at different stages. The invention provides a planting method for promoting delayed picking of kiwifruit, which can improve the survival rate of kiwifruit, prevent diseases and insect pests and promote delayed maturing of kiwifruit, is suitable for large-scale systematic planting, and can increase the yield and income for farmers.

The invention relates to the technical field of stem cells, in particular to a stem cell preparation for treating knee joint degenerative change and a preparation method thereof. A DMEM LG/F12 basic culture medium, 10% human platelet lysis buffer and 10g/L basic fibroblast growth factors are adopted as culture solutions; 10nM of dexamethasone, 25mu g/mL of vitamin C and 2mM of beta-glycerophosphate are used as chondrogenesis induced differentiation agents, so that the culture of the umbilical cord mesenchymal stem cells is successfully realized. The serum-free culture solution used in the invention can achieve the same culture effect as a culture solution containing serum in a contrast; due to the fact that the used culture solution is clear in component, compared with a culture solution containing fetal calf serum, introduction of animal exogenous substances is avoided, and risks caused by serum to cell culture can be avoided to the maximum extent.

The invention discloses application of an AK2 gene in preparation of a leukemia induced differentiation treatment medicine. According to the invention, the differentiation of leukemia cells can be directly induced by reducing the expression of AK2 by using an siRNA interference technology. Therefore, it is proposed for the first time that the AK2 gene is a key gene for leukemia induced differentiation treatment, siRNAs molecules of the AK2 can be used as a leukemia induced differentiation agent, a new treatment target is provided for induced differentiation treatment of leukemia, and the AK2 gene plays an important role in treatment of leukemia. The invention provides possibilities for preparing novel drugs for induced differentiation of leukemia, improving the curative effect of leukemia patients and improving drug resistance and related prognosis conditions.

The present invention concerns preventative, therapeutic, and diagnostic methods and compositions involving UC markers, such as UC 28, for cancer. It includes methods and compositions for targeting cancer cells using a differentiation agent in combination with a therapeutic agent targeted to cells that differentially express a UC marker after exposure to the differentiation agent. The invention also includes methods of inducing immune responses against UC markers, as well as antibodies that recognize UC markers, which may be employed for therapeutic and diagnostic methods.

Methods for differentiation of cells of a rat liver epithelial (RLEC) cell line to hepatocyte-like cells are disclosed. In particular, methods involve sequential exposure of the RLEC to two or more differentiation agents. Cells obtained by the method are described as well as their uses in various pharmacological, toxicological, therapeutic, diagnostic and research applications.